NCT03423225 is a Phase 4 clinical trial of ADVAGRAF® in Liver Transplantation, sponsored by Kim, Seoung-Hoon.

Who is sponsoring NCT03423225?

NCT03423225 is sponsored by Kim, Seoung-Hoon.

What drugs are being tested in NCT03423225?

Interventions in NCT03423225: ADVAGRAF®.

What condition does NCT03423225 study?

NCT03423225 studies Liver Transplantation.

Is NCT03423225 still recruiting?

NCT03423225 is currently completed. Last updated 6 February 2018.

Last reviewed 2018-02-06 · How we verify

NCT03423225

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

To Evaluate the Efficacy and Safety of ADVAGRAF® After Treatment With a Tacrolimus in New Liver Transplant Recipients

Completed Phase 4 Last updated 6 February 2018

What this trial tests

Phase 4 trial testing ADVAGRAF® in Liver Transplantation in 31 participants. Completed in 14 December 2017.

Timeline

22 March 2016

Primary endpoint
18 July 2017

14 December 2017

Quick facts

Lead sponsor	Kim, Seoung-Hoon
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	31
Start date	22 March 2016
Primary completion	18 July 2017
Estimated completion	14 December 2017

Drugs / interventions tested

ADVAGRAF®

Conditions studied

Liver Transplantation — all drugs for Liver Transplantation →

Sponsor

Kim, Seoung-Hoon

Who can join

20 and older, any sex, with Liver Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study's objective is to evaluate the incidence rate of acute rejection reactions after 24 weeks treatment with ADVAGRAF® following 3 months treatment with tacrolimus in new liver transplant recipients. Treatment conversion will take place from twice daily tacrolimus to once daily tacrolimus (ADVAGRAF) 3 months after transplant in new liver transplant recipients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Safety and Efficacy of Once-Daily Prolonged-Release Tacrolimus in Living Donor Liver Transplantation: An Open-Label, Prospective, Single-Arm, Phase 4 Study.
Lee EC, Kim SH, Park SJ. · · 2018 · cited 2× · PMID 30310047 · DOI 10.12659/aot.910618

Verify or expand the search:

Other recruiting trials for Liver Transplantation

Currently open trials in the same condition.

NCT07157631 — Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial · NA · recruiting
NCT07123740 — Comparison of the Postoperative Analgesic Effects of ITM and Bi-level ESPB in Liver Transplantation Donors · NA · recruiting
NCT06717919 — HOPE Against Cancer Recurrence in HCC · Phase 4 · recruiting
NCT06868589 — Reducing Pain With Methadone and Ketamine in Liver Transplant · Phase 4 · active not recruiting
NCT06874296 — Assessing Declined Liver Grafts With Normothermic Machine Perfusion to Reduce Transplant Waiting Time · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03423225 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kim, Seoung-Hoon
Last refreshed: 6 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03423225.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing